ArticleJournal of neurology2024

Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.

S Doubrovinskaja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.